2
Post your comment
Last update: 10 January 2014
The Colombian Ministry of Health and Social Protection (Ministerio de Salud y Protección Social de Colombia) announced on 21 January 2013 the release of a new draft guideline for biologicals, including productos bioterapéuticos similares (similar biotherapeutic products), in Colombia.
Regulations for the registration of biological products were implemented in Colombia in 1995 through Ministerial Decree 677/1995.
Biologicals are defined in Colombia as products obtained from: a) sources such as living organisms, or parts of these tissues, viruses, serums, toxins, antitoxins, blood, blood-derived components, allergenic products, hormones, growth factors, cytokines, antibodies; and b) produced by methods including but not limited to: cell culture, cultures of micro-organisms, extraction from tissues or biological fluids, recombinant DNA techniques, transgenesis, hybridoma techniques and spread of micro-organisms embryos or animals.
The proposed draft decree provides for three routes for biological products: a complete route, a comparability route and an abbreviated route which aims to facilitate the registration of productos bioterapéuticos similares.
The proposed draft decree aims to facilitate the registration of biosimilar products in Colombia through an abbreviated pathway.
Draft decree drug registration and monitoring biological and biotechnological origin
Date: 21 January 2013
www.minsalud.gov.co/Normatividad/Biológicos%20y%20Biotecnológicos%20Tercera%20Versión.pdf
This proposed draft decree aims to enable the establishment of standards and regulatory procedures to ensure the quality, safety and efficacy of productos bioterapéuticos similares available in Colombia. However, although declaring that the required information must show the quality, efficacy and safety of the medicine there are no specifications as to how these properties should be demonstrated by the applicant.
The draft was released for public consultation and feedback could be given via the Ministry of Health and Social Protection (Cra.13#32-76 Bogota D.C), with a copy to storres@minsalud.gov.co. Written submissions and comments on the new version were accepted by the Ministry of Health and Social Protection for a period of one month until 21 February 2013.
The ministry published proposed changes to the draft on its website on 25 June 2013 and published comments received after the fourth round of discussions on the draft decree on 12 September 2013. To date, however, the Ministry has still not published finalized guidance.
Editor’s comment
It should be noted that productos bioterapéuticos similares approved in Colombia might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.
If you would like to receive a copy* of the proposed draft decree, please email us.
*For profit organizations subjected to a fee
Related articles
Egypt issues draft guidelines for biosimilars
India releases draft ‘similar biologic’ guidelines
FDA finally issues draft biosimilar guidance
Global guidelines for biosimilars
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: Ministerio de Salud y Protección Social de Colombia
Dear Mr Gundecha,
No, what we mean is that biosimilars approved in Colombia might not be authorized following as strict a regulatory process as is required for approval of biosimilars in the EU.
Thank you and regards,
Michelle
Please publish an English version of the guideline.
Do you mean that biosimilars which are not approved by EMA will not be able to registered in Colombia?
NPRA Malaysia trials new timelines for variation applications
Los nueve fármacos biológicos más vendidos en 2023
Nuevos hallazgos de semaglutida en el tratamiento de la hidradenitis supurativa
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
¡Regístrese hoy para recibir información semanal sobre los últimos avances en medicamentos genéricos y biosimilares!
Post your comment